"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
| Descriptor ID |
D000736
|
| MeSH Number(s) |
D04.210.500.054.079
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androstenes".
Below are MeSH descriptors whose meaning is more specific than "Androstenes".
This graph shows the total number of publications written about "Androstenes" by people in this website by year, and whether "Androstenes" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Androstenes" by people in Profiles.
-
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026 Jan; 37(1):53-68.
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial. JAMA Netw Open. 2024 07 01; 7(7):e2419966.
-
Cardiovascular Toxicities of Androgen Deprivation Therapy. Curr Treat Options Oncol. 2021 04 17; 22(6):47.
-
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Ann Oncol. 2021 07; 32(7):896-905.
-
Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review. Oncology. 2019; 97(5):301-305.
-
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 05; 73(5):715-723.
-
New targets for resistant prostate cancer. Oncotarget. 2014 Oct 15; 5(19):8816-7.
-
Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol. 2008 Jan; 58(1):60-2.
-
Effects of finasteride on the rat ventral prostate. J Androl. 1993 Mar-Apr; 14(2):79-86.